1. Home
  2. Directory
  3. Massachusetts
  4. Boston
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1982809463

DR. SUSANNA B MIERAU MD, DPHIL
Prescription History 1982809463
Psychiatry & Neurology - Neurology in Boston, MA

NPI Status: Active since June 15, 2007

Contact Information

60 FENWOOD RD
BOSTON, MA
ZIP 02115
Phone: (617) 732-8060

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SUSANNA B MIERAU MD, DPHIL, an active Neurology specialist practicing in Boston, MA. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 170 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 39 claims alone.

Medication Index

Divalproex Sodium

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 22
30-Day Fills 40.0
Days Supply 1,198
MA State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills58.3
Peer Average Days Supply1,519
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,383.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.88

State Avg Cost Per Claim

$55.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Divalproex Sodium Er

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 26.0
Days Supply 780
MA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills47.8
Peer Average Days Supply1,372
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,392.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$466.28

State Avg Cost Per Claim

$106.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Fluvoxamine Maleate

Generic Formulation: Fluvoxamine MaleateSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
MA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills37.3
Peer Average Days Supply1,006
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.6% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $534.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.63

State Avg Cost Per Claim

$45.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.

Therapeutic Applications

Fluvoxamine is used to treat obsessive-compulsive disorder (OCD). It helps decrease thoughts that are unwanted or that don't go away (obsessions), and it helps to reduce the urge to perform repeated tasks (compulsions such as hand-washing, counting, checking) that interfere with daily living. Fluvoxamine is known as a selective serotonin reuptake inhibitor (SSRI). This medication works by helping to restore the balance of a certain natural substance (serotonin) in the brain.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 29
30-Day Fills 39.8
Days Supply 1,194
MA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills35.2
Peer Average Days Supply992
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $548.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.91

State Avg Cost Per Claim

$336.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 39
30-Day Fills 41.0
Days Supply 1,215
MA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills71.7
Peer Average Days Supply2,011
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,826.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.84

State Avg Cost Per Claim

$42.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Oxcarbazepine

Generic Formulation: OxcarbazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 27
30-Day Fills 33.0
Days Supply 990
MA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills50.3
Peer Average Days Supply1,440
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $956.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.42

State Avg Cost Per Claim

$63.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Therapeutic Applications

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).

Sertraline Hcl

Generic Formulation: Sertraline HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 27.0
Days Supply 810
MA State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills109.1
Peer Average Days Supply3,171
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.0% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $562.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.86

State Avg Cost Per Claim

$11.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Sertraline is used to treat depression, panic attacks, obsessive compulsive disorder, post-traumatic stress disorder, social anxiety disorder (social phobia), and a severe form of premenstrual syndrome (premenstrual dysphoric disorder). This medication may improve your mood, sleep, appetite, and energy level and may help restore your interest in daily living. It may decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. It may also reduce the urge to perform repeated tasks (compulsions such as hand-washing, counting, and checking) that interfere with daily living. Sertraline is known as a selective serotonin reuptake inhibitor (SSRI). It works by helping to restore the balance of a certain natural substance (serotonin) in the brain.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 32.0
Days Supply 940
MA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills51.2
Peer Average Days Supply1,477
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,154.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$96.18

State Avg Cost Per Claim

$38.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SUSANNA B MIERAU MD, DPHIL provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.